0H22
:LSE

Add to watchlist
46,96 kr
Last updated:11/26/2021
0H22: LSE
46,96 kr
Bioinvent International AB

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, rest of Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206, a monoclonal antibody targeting CD32b, which is in Phase I/IIa clinical trials in patients with B-cell non-Hodgkin lymphoma and chronic…

P/E ratio
-
vs. 0.00x forward
Stock volatility (Beta)
past 12 months
Become our supporter to unlock all data!
Company profile
CEO
Not defined
Website
Market capitalization
Not defined